Informationen:
Fehler:
ID
14031
Beschreibung
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02319135
Link
https://clinicaltrials.gov/show/NCT02319135
Stichworte
Versionen (1)
- 22.03.16 22.03.16 -
Hochgeladen am
22. März 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Acute Myeloid Leukemia NCT02319135
Eligibility Acute Myeloid Leukemia NCT02319135
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Acute Myeloid Leukemia NCT02319135
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Informed Consent
Item
Having voluntarily given informed consent before performing any test that is not part of
boolean
C0021430 (UMLS CUI [1])
Routine care
Item
Routine care of patients.
boolean
C1547137 (UMLS CUI [1])
Age
Item
Age greater than or equal to 65.
boolean
C0001779 (UMLS CUI [1])
AML
Item
Morphological diagnosis of non-promyelocytic aml according to the who criteria.
boolean
C0023467 (UMLS CUI [1])
ECOG
Item
Ecog performance status <4.
boolean
C1520224 (UMLS CUI [1])
Compliance with study
Item
Ability and willingness to comply with the schedule of study visits.
boolean
C0525058 (UMLS CUI [1])
Acute Promyelocytic Leukemia
Item
Genetic diagnosis of acute promyelocytic leukemia.
boolean
C0023487 (UMLS CUI [1])
aml secondary to myelodysplastic syndrome
Item
Patients with aml secondary to myelodysplastic syndrome (mds) or chronic myeloproloferative syndrome who have been previously treated with antileukemic agents
boolean
C0280449 (UMLS CUI [1])
chemotherapy
Item
hypomethylating or standard chemotherapy.
boolean
C3665472 (UMLS CUI [1])
serum creatinine
Item
serum creatinine ≥ 250 mmol / l (≥ 2.5 mg/dl) (unless attributed to aml).
boolean
C0600061 (UMLS CUI [1])
bilirubin, alkaline phosphatase
Item
bilirubin, alkaline phosphatase or alt > 5 times the value of the upper limit of normal (unless attributed to aml) .
boolean
C0005437 (UMLS CUI [1])
C0002059 (UMLS CUI [2])
C0002059 (UMLS CUI [2])
Life-threatening disease
Item
presence of an active and/or non controlled pathology different to aml which is severe and life-threatening, that in the investigator's opinion, prevents the subject participation in the study.
boolean
C1517874 (UMLS CUI [1])
concomitant disease
Item
other active concomitant malignancy or whose remission is less than one year from the screening day (except carcinoma in situ).
boolean
C0243087 (UMLS CUI [1])
Mental disorders
Item
presence of any psychiatric illness or medical condition that, in the investigator's opinion, prevents the subject participation in the study.
boolean
C0004936 (UMLS CUI [1])
life expectancy
Item
life expectancy less than x months.
boolean
C0023671 (UMLS CUI [1])
No informed consent
Item
inability of the patient or his legal representative to understand and voluntarily sign the informed consent form.
boolean
C0021430 (UMLS CUI [1])